Up­dat­ed: No­var­tis trims pipeline by 10% as Vas Narasimhan places pre­mi­um on 'high-val­ue med­i­ci­nes'

No­var­tis is shed­ding around 10% of its pipeline as Vas Narasimhan’s cam­paign to turn it in­to a “pure-play” drug­mak­er goes full steam.

Fol­low­ing a com­pre­hen­sive …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER